Try our Advanced Search for more refined results
Life Sciences
- 
									October 14, 2025
									Covington, Sidley Guide $700M BioCryst Allergic Disease DealBioCryst Pharmaceuticals Inc. will purchase Astria Therapeutics Inc., a biopharmaceutical company focused on therapies for allergic and immunologic diseases, in a cash and stock deal worth about $700 million, the companies announced Tuesday. 
- 
									October 14, 2025
									High Court Won't Hear FDA Stem Cell Regulation FightThe U.S. Supreme Court on Tuesday declined to review a circuit court holding that a stem cell treatment derived from a patient's own tissue is subject to Food, Drug and Cosmetic Act regulations. 
- 
									October 10, 2025
									Some Cases Advance In Latest Stewart Discretionary RulingsDeputy U.S. Patent and Trademark Office Director Coke Morgan Stewart rejected 37 Patent Trial and Appeal Board petitions Friday night, but allowed 17 challenges to proceed. 
- 
									October 10, 2025
									Zantac MDL Suits Were Impropely Tossed, 11th Circ. ToldConsumers urged the Eleventh Circuit on Friday to revive their claims in a multidistrict litigation alleging that the main ingredient in the heartburn medication Zantac causes cancer, saying the court overseeing the case improperly sided with drugmakers' experts and preempted more claims from coming forward. 
- 
									October 10, 2025
									Federal Worker Unions Press For Immediate Block Of LayoffsUnions representing federal workers urged a California federal court Friday to immediately block the Trump administration from laying off workers amid the government shutdown as the administration acknowledged it had begun issuing reduction-in-force notices to thousands of employees. 
- 
									October 10, 2025
									AstraZeneca Strikes 'Most Favored Nation' Price DealPharmaceutical giant AstraZeneca on Friday cut a deal with the Trump administration to reduce drug prices in the United States, agreeing to provide its medications for Medicaid beneficiaries at discount prices. 
- 
									October 10, 2025
									ATyr Pharma Faces Investor Suit Over Failed Drug TrialRare disease biotech aTyr Pharma Inc. and its CEO have been hit with a proposed shareholder class action accusing them of misleading the public about the efficacy of aTyr's lung disease treatment for several months before announcing its trial had not yielded favorable results. 
- 
									October 10, 2025
									Profs Say Apple Used Copyrighted Material For AI TrainingTwo neuroscientists have sued Apple in California federal court, claiming it made use of their copyrighted materials to train its artificial intelligence model Apple Intelligence. 
- 
									October 10, 2025
									Covington, Goodwin Guide Bristol Myers' $1.5B Orbital BuyBristol Myers Squibb plans to acquire privately held Orbital Therapeutics for $1.5 billion in cash, aiming to expand its pipeline in cell- and RNA-based therapies for autoimmune diseases, the companies announced Friday. 
- 
									October 10, 2025
									Pharma Co. Escapes Suit Over Ex-CEO's Alleged MisconductExscientia PLC on Friday won dismissal of a proposed class action related to the termination of its CEO after claims emerged that he participated in inappropriate workplace relationships, with the court finding the investors failed to show that the company's statements about its culture and governance were anything more than puffery. 
- 
									October 10, 2025
									Clinical Trial Co. Settles Severance Fight With Ex-VPA clinical research company has agreed to shutter a lawsuit from an ex-executive who claimed his requests for severance went ignored following his resignation, according to a Friday filing in North Carolina federal court. 
- 
									October 10, 2025
									UK Litigation Roundup: Here's What You Missed In LondonThis past week in London has seen Paddington Bear's creators and Studio Canal sue the company behind Spitting Image, Blackpool Football Club's former owner Owen Oyston bring a fresh claim against the club, and Mishcon de Reya sue a Saudi investment group. 
- 
									October 09, 2025
									Justices Urged To Clarify Patent Validity In Entresto CaseGeneric-drug makers, academics and others are urging the U.S. Supreme Court to take a case involving Novartis' blockbuster cardiovascular drug Entresto, saying the justices must bring consistency to conflicting Federal Circuit precedent on the role of later technology in assessing patent validity. 
- 
									October 09, 2025
									Biotronik Wants Full 9th Circ. Review Of Whistleblower RulingBiotronik Inc. urged the full Ninth Circuit to review a panel ruling that revived a whistleblower suit alleging the company used unlawful compensation tactics to boost heart-device sales, saying it should have been tossed based on prior disclosures in news articles. 
- 
									October 09, 2025
									Pharma Co. Looks To Nix 'Absurd' Award Over Acne DrugSun Pharmaceutical Industries is urging a New York federal court to partially undo an arbitral award issued in a dispute over intellectual property for an acne drug, saying the award, if allowed to stand, could interfere with a medication that's been available in Canada for years. 
- 
									October 09, 2025
									9th Circ. Probes Buyers On HIV Drug Antitrust ClaimsInsurers and health plans told a Ninth Circuit panel on Thursday that a lower court was wrong to toss their claims that Gilead orchestrated a product-hop scheme for its HIV drugs ahead of trial and for not seeing a price drop as evidence of an alleged agreement with Teva to delay generics. 
- 
									October 09, 2025
									NJ Justices Probe Insurer's Role In $12M Settlement FightThe New Jersey Supreme Court zeroed in Thursday on how far insurers can go in reserving their rights without taking a definitive position on coverage, as Mist Pharmaceuticals LLC accused Berkley Insurance Co. of stonewalling a $12 million settlement by hiding behind ambiguity in its "capacity exclusion" clause. 
- 
									October 09, 2025
									Mich. Justice Eyes Scope Of Judge-As-Grand-Jury IssueMichigan's chief Supreme Court justice on Thursday pondered the real-world implications of retroactively applying a 2022 ruling that judges cannot act as a one-person grand jury to issue indictments, saying the practice seems to have grown more prevalent. 
- 
									October 09, 2025
									Judge Axes Cell Analysis Patent In Case Against ParseA federal magistrate judge in Delaware has trimmed a suit accusing biotechnology company Parse Biosciences of infringing patents covering a way of detecting target molecules in cell samples, finding one of the patents was invalid. 
- 
									October 09, 2025
									Hemp Co. Asks Del. Court To Defer Ex-Exec's Suit To AustraliaAn Australian hemp manufacturer and its U.S. subsidiaries asked a Delaware federal judge Thursday to dismiss or pause a lawsuit filed by a former executive-turned-whistleblower, arguing the case should be deferred under international comity principles. 
- 
									October 09, 2025
									Tivity Health Investors Seek Final OK Of $17M SettlementAn investor in fitness program administrator Tivity Health Inc. has asked a Nashville federal judge for a final nod for an over $17 million deal ending claims the company misled investors about its financial prospects after its $1.3 billion acquisition of troubled weight-loss meal delivery company Nutrisystem. 
- 
									October 09, 2025
									Pet Owner Keeps State, But Not Fed., Elanco Tick Meds SuitAdvantix flea-and-tick medication maker Elanco Animal Health Inc. partially ducked a consumer proposed class action by convincing an Indiana federal judge to cut federal antitrust claims, but still must face state law allegations accusing it of paying off PetSmart, Petco and Chewy not to carry generic versions. 
- 
									October 09, 2025
									Patient Asks 4th Circ. To Revive Faulty Ethicon Stapler SuitA surgery patient is asking the Fourth Circuit to reinstate his suit against Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC over faulty staples used in his procedure, saying the district court was wrong to deny his request to extend an expert deadline after he finally narrowed down the type of stapler used. 
- 
									October 09, 2025
									Ropes, Kirkland Guide $5.2B Novo Nordisk Liver Disease DealNovo Nordisk said on Thursday it will acquire U.S.-based Akero Therapeutics for up to $5.2 billion in cash, expanding its portfolio into metabolic liver disease in a deal steered by Ropes & Gray LLP and Kirkland & Ellis LLP. 
- 
									October 09, 2025
									Munck Wilson Taps Texas Atty To Lead Life Sciences PracticeMunck Wilson Mandala LLP has chosen a Lone Star State lawyer who joined the firm earlier this year to lead the technology-focused firm's life sciences practice group. 
Expert Analysis
- 
								
								Advice For 1st-Gen Lawyers Entering The Legal Profession  Nikki Hurtado at The Ferraro Law Firm tells her story of being a first-generation lawyer and how others who begin their professional journeys without the benefit of playbooks handed down by relatives can turn this disadvantage into their greatest strength. 
- 
								
								High Court E-Cig Ruling Opens Door For FDA Challenges  There will likely be more challenges to marketing denial orders brought before the Fifth Circuit following the Supreme Court's recent ruling in U.S. Food and Drug Administration v. R.J. Reynolds Vapor Co., where litigants have generally had greater success, say attorneys at Troutman Pepper. 
- 
								
								Fed. Circ. In July: Instability In IPR Requirements  The Federal Circuit's decision in Shockwave v. Cardiovascular last month provided an important, albeit short-lived, clarification to the type of evidence that can be used in an inter partes review challenge, say attorneys at Knobbe Martens. 
- 
								
								Structuring Noncompetes In License And Collaboration Deals.jpg)  As companies grappling with coming patent cliffs look to mergers and acquisitions to compensate, contracting parties assessing biopharma license and collaboration agreements should prepare to agree on noncompetes that ensure the parties' respective objectives are met and that their incentives are aligned, both under their collaboration and beyond, says Jeff Jay at Freshfields. 
- 
								Series Coaching Cheerleading Makes Me A Better Lawyer  At first glance, cheerleading and litigation may seem like worlds apart, but both require precision, adaptability, leadership and the ability to stay composed under pressure — all of which have sharpened how I approach my work in the emotionally complex world of mass torts and personal injury, says Rashanda Bruce at Robins Kaplan. 
- 
								
								7 Ways To Fetch Patents In The World Of Working Animals  Though developers rarely file patents related to working animals, and animal training techniques are generally considered unpatentable, certain aspects of training and developing animals may be ripe for patent protection, say Matthew Avery at Baker Botts, Makenzi Galvan at Perkins Coie and Lute Yang at Orrick. 
- 
								
								9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool  The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill. 
- 
								Series Law School's Missed Lessons: How To Make A Deal  Preparing lawyers for the nuances of a transactional practice is not a strong suit for most law schools, but, in practice, there are six principles that can help young M&A lawyers become seasoned, trusted deal advisers, says Chuck Morton at Venable. 
- 
								
								From Clerkship To Law Firm: 5 Transition Tips For AssociatesExcerpt from  Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler. 
- 
								
								9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs  The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley. 
- 
								
								Associates Can Earn Credibility By Investing In Relationships  As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron. 
- 
								
								Puzzling Out When Similar Insurance Claims Are Related  A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton. 
- 
								
								A Shifting Trend In FDA Form 483 Disclosure Obligations  A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird. 
- 
								
								Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop  There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan. 
- 
								
								Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling  The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law. 
